diabetestalk.net

Staging Presymptomatic Type 1 Diabetes

New Staging System For Presymptomatic Type 1 Diabetes

New Staging System For Presymptomatic Type 1 Diabetes

New Staging System for Presymptomatic Type 1 Diabetes Released by JDRF, the Endocrine Society, and the American Diabetes Association Commentary by Richard Insel MD, Desmond Schatz MD, and Kevan Herold MD A new approach for staging T1D in its earliest presymptomatic stages was released by the JDRF, the Endocrine Society, and the American Diabetes Association. The organizations endorse the concept that autoimmune disease precedes the onset of symptoms and progresses through distinct stages, as reported in the October issue of Diabetes Care. Stage 1: individuals who are normoglycemic but test positive for 2 or more type 1 diabetesassociated islet autoantibodies. Stage 2: individuals with 2 or more islet autoantibodies who have developed glucose intolerance or dysglycemia, from loss of functional -cell mass. Stage 3: individuals who have symptoms of type 1 diabetes, such as polyuria, polydipsia, weight loss, fatigue, and diabetic ketoacidosis. While the rate of progression between stages is variable among individuals, the risk can be defined, which may facilitate clinical trials that aim to preserve functional insulin-producing beta cells, according to the associations. In addition, while approximately 50 genetic variants that increase susceptibility to T1D have been discovered; 85% to 90% of individuals newly diagnosed with T1D have no history of T1D among their relatives, the associations noted. We know type 1 diabetes begins long before insulin dependence occurs, and the best time to halt the diseases progress is before the loss of insulin-producing pancreatic beta cells, Chief Scientific Officer of JDRF Richard Insel, MD, said in a statement to the press. Decades of research in at-risk individuals have provided the foundation for developing this new 3-stage diagnostic Continue reading >>

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association

N2 - Insights fromprospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of b-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of b-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease. AB - Insights fromprospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of b-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of b-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent sympto Continue reading >>

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association Insel, R.A.; Dunne, J.L.; Atkinson, M.A.; Chiang, J.L.; Dabelea, D.; Gottlieb, P.A.; Greenbaum, C.J.; Herold, K.C.; Krischer, J.P.; Lernmark, ke.; Ratner, R.E.; Rewers, M.J.; Schatz, D.A.; Skyler, J.S.; Sosenko, J.M.; Ziegler, A-G. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of -cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of -cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease. Continue reading >>

Type 1 Diabetes: Disease Stratification

Type 1 Diabetes: Disease Stratification

Type 1 diabetes, a disorder characterized by immune-mediated loss of functional pancreatic beta cells, is a disease continuum with specific presymptomatic stages with defined risk of progression to symptomatic disease. Prognostic biomarkers have been developed for disease staging and for stratification of subjects that address the heterogeneity in rate of disease progression. Using biomarkers for stratification of subjects at different stages of type 1 diabetes will enable smaller and shorter intervention clinical trials with greater effect size. Addressing the heterogeneity of the disease will allow precision medicine-based approaches to prevention and interception of presymptomatic stages of disease and treatment and cure of symptomatic disease. 2017 The Author(s) Published by S. Karger AG, Basel Type 1 diabetes (T1D) is a chronic, immune-mediated disease associated with destruction of the insulin-producing beta cells of the islets of the pancreas [ 1 ]. Approximately 40-50% of the risk of disease arises from genetics with the remaining risk arising from poorly defined environmental etiologies. The class I and II human leukocyte antigen (HLA) genes contribute about half of the genetic risk of disease with about 40-50 non-HLA genes accounting for the remainder of genetic risk [ 2 , 3 , 4 ]. The most prominent associated HLA genes are HLA class II haplotypes DRB1*0301-DQB1*0201 (DR3-DQ2) and DRB1*0401-DQB1*0302 (DR4-DQ8) with the highest risk occurring in the heterozygous DR3/4 genotype. Non-HLA genes include INS, CTLA4, PTPN22, and IL2RA in addition to multiple non-HLA SNPs that have been mapped to DNA regulatory sequences of immune cells [ 4 , 5 ]. Several non-HLA susceptibility genes are expressed in human islets, and cytokines can alter their expression in the isle Continue reading >>

Jdrf And The American Diabetes Association, In Collaboration With Multiple Diabetes Organizations Publish New Classification And Staging Approach For Presymptomatic Type 1

Jdrf And The American Diabetes Association, In Collaboration With Multiple Diabetes Organizations Publish New Classification And Staging Approach For Presymptomatic Type 1

JDRF and the American Diabetes Association, in Collaboration with Multiple Diabetes Organizations Publish New Classification and Staging Approach for Presymptomatic Type 1 Diabetes Organizations Endorse Concept that Autoimmune Disease Begins Long Before Symptoms Occur and Progresses through Distinct Stages, which Provide a Window of Opportunity to Intervene and Prevent Symptomatic Disease JDRF and the American Diabetes Association (Association), announced today that a new classification approach for staging T1D in its earliest presymptomatic stages would be published in the September 24th online version of Diabetes Care. JDRF convened a group of leading diabetes research and clinical organizations to develop the staging approach, which was published as a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association and endorsed by the American Association of Clinical Endocrinologists, the International Society for Pediatric and Adolescent Diabetes, and The Leona M. and Harry B. Helmsley Charitable Trust. The pre-clinical staging model embraces the concept that T1D begins prior to symptomatic disease and then progresses to a point of certainty for insulin replacement. The staging approach will aid the development of therapies and the design of clinical trials to prevent symptomatic disease and promote precision medicine. Finally, the staging approach will provide a framework to help inform benefit/risk evaluation in the regulatory, reimbursement, and clinical care settings. "We know type 1 diabetes begins long before insulin dependence occurs, and the best time to halt the disease's progress is before the loss of insulin-producing pancreatic beta cells," said JDRF's Chief Scientific Officer, Richard Insel, M.D. "Decades of research in at-ris Continue reading >>

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association 11Institute of Diabetes Research, Helmholtz Zentrum Mnchen, Munich and Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universitt Mnchen, Neuherberg, Germany 2UF Diabetes Institute, University of Florida, Gainesville, FL 3American Diabetes Association, Alexandria, VA 4Colorado School of Public Health, University of Colorado, Denver, CO 5Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO 6Benaroya Research Institute at Virginia Mason, Seattle, WA 7Department of Immunobiology, Yale School of Medicine, New Haven, CT 8Department of Pediatrics, Pediatric Epidemiology Center, Morsani College of Medicine, University of South Florida, Tampa, FL 9Lund University/Clinical Research Centre, Skne University Hospital, Malm, Sweden 10Diabetes Research Institute, University of Miami, Miami, FL 11Institute of Diabetes Research, Helmholtz Zentrum Mnchen, Munich and Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universitt Mnchen, Neuherberg, Germany See " Guiding Principles for Diabetes Care " in volume 38 onpage1955. This article has been cited by other articles in PMC. Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of -cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of -cell autoimmunity with dysglycemia and is presymptomatic, and Continue reading >>

Frontiers | Understanding Pre-type 1 Diabetes: The Key To Prevention | Endocrinology

Frontiers | Understanding Pre-type 1 Diabetes: The Key To Prevention | Endocrinology

Front. Endocrinol., 06 March 2018 | Understanding Pre-Type 1 Diabetes: The Key to Prevention Division of Endocrinology, Department of Pediatrics, University of Florida, Gainesville, FL, United States While the incidence of type 1 diabetes continues to rise by 3% each year, the ability to prevent this disease remains elusive. Hybrid closed loop devices, artificial pancreas systems, and continuous glucose monitoring technology have helped to ease the daily burden for many people living with type 1 diabetes. However, the artificial pancreas is not a cure; more research is needed to achieve our ultimate goal of preventing type 1 diabetes. The preceding decades have generated a wealth of information regarding the natural history of pre-type 1 diabetes. Islet autoimmunity in the form of multiple autoantibodies is known to be highly predictive of progression to disease. Staging systems have been devised to better characterize pre-type 1, direct mechanistic understanding of disease, and guide the design of prevention studies. However, there are no evidence-based recommendations for practitioners caring for autoantibody patients other than to encourage enrollment in research studies. Close monitoring of high-risk patients in natural history studies markedly reduces diabetic ketoacidosis rates at diagnosis and research participation is critical to finding a means of preventing type 1 diabetes. The discovery of an effective preventative strategy for type 1 diabetes will justify universal risk screening for all children. As is the case for type 2 diabetes, the incidence and prevalence of type 1 diabetes is increasing annually. It is estimated that more than 542,000 children worldwide have type 1 diabetes. With the diagnosis of type 1 diabetes rising by 23% per year, 86,000 childre Continue reading >>

Staging Presymptomatic Type 1 Diabetes

Staging Presymptomatic Type 1 Diabetes

Progression through 3 identifiable phases noted The Juvenile Diabetes Research Foundation, the Endocrine Society, and the American Diabetes Association have published a statement entitled, Staging Presymptomatic Type 1 Diabetes. It draws on data and insights from prospective and longitudinal studies of those at risk of developing type 1 diabetes. The authors note that type 1 diabetes is a continuum that progresses through identifiable stages before disease onset. Specifically: Stage 1 is marked by the presence of beta-cell autoimmunity, manifested by the presence of 2 or more islet autoantibodies with normoglycemia. It is presymptomatic at this stage. Stage 2 also has the presence of beta-cell autoimmunity, but with dysglycemia. It is presymptomatic at this stage, as well. Stage 3 marks the onset of symptomatic disease. The authors explained that adopting such system allows for a staging classification for type 1 diabetes that will, among other things, facilitate the development of targeted therapies and promote precision medicine. Citation: Insel R, Dunne J, Atkinson M, et al. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 2015;38:19641974. Continue reading >>

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association.

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association.

Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. UF Diabetes Institute, University of Florida, Gainesville, FL. American Diabetes Association, Alexandria, VA. Colorado School of Public Health, University of Colorado, Denver, CO. Barbara Davis Center for Childhood Diabetes, University of Colorado, Aurora, CO. Benaroya Research Institute at Virginia Mason, Seattle, WA. Department of Immunobiology, Yale School of Medicine, New Haven, CT. Department of Pediatrics, Pediatric Epidemiology Center, Morsani College of Medicine, University of South Florida, Tampa, FL. Lund University/Clinical Research Centre, Skne University Hospital, Malm, Sweden. Diabetes Research Institute, University of Miami, Miami, FL. Institute of Diabetes Research, Helmholtz Zentrum Mnchen, Munich and Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universitt Mnchen, Neuherberg, Germany. Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of -cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of -cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic Continue reading >>

The Type 1 Diabetes Stages

The Type 1 Diabetes Stages

A common question at diagnosis is, Could this have been coming on for a while? The usual answer is, No, Type 1 diabetes comes on very suddenly, in a matter of weeks, as the bodys beta cells suddenly die out under attack from the immune system. But it turns out they were wrong. Three type 1 diabetes stages have been identified and described. JDRF and the American Diabetes Association, supported by other organizations in the field, recently put forth a new staging system for type 1 diabetes, where full-blown disease is characterized as stage 3, part of an extended autoimmune process that often starts in infancy. This fall, Dr. Richard Insel, JDRFs Chief Scientific Officer, explained the classification system to a group of reporters, talking through the importance of early diagnosis, and the hope that diagnosing the disease at an earlier stage could lead to breakthroughs in stopping the beta-cell destruction processessentially, stopping the disease before it starts. Insel explained that stage 1 is when people test positive for multiple pancreatic islet auto-antibodies, meaning that the immune system has begun to attack the pancreas. If you are a sibling of a person with type 1 diabetes, you can get tested for these auto-antibodies,through TrialNet. (1) our children who do not have diabetes are tested every year, since siblings are at greater risk than others. In stage 2, people start processing glucose differently. While people in stage 2 are not yet experiencing the classic signs of type 1 diabetes (weight loss, tiredness, excessive thirst and polyuria), if given a glucose-tolerance test, their blood sugar would rise more than normal. The HbA1c (a measure of average blood glucose level over a three-month period) might also start rising above normal. The abstract for the Continue reading >>

Diabetes Groups Issue Staging Guidance For Type 1 Diabetes

Diabetes Groups Issue Staging Guidance For Type 1 Diabetes

Diabetes Groups Issue Staging Guidance for Type 1 Diabetes This article is intended for primary care clinicians, diabetologists, endocrinologists, cardiologists, nurses, pharmacists, and other members of the healthcare team involved in the care of patients with type 1 diabetes. The goal of this activity is to provide medical news to primary care clinicians and other healthcare professionals in order to enhance patient care. Upon completion of this activity, participants will be able to: Describe a new type 1 diabetes staging classification developed by the Juvenile Diabetes Research Foundation and the American Diabetes Association Determine the potential usefulness of the new type 1 diabetes staging classification developed by the Juvenile Diabetes Research Foundation and the American Diabetes Association As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content. Disclosure: Miriam E. Tucker has disclosed no relevant financial relationships. Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships. Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevan Continue reading >>

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association

Diabetes Care 2015;38:19641974 |DOI: 10.2337/dc15-1419 The Adoption of the Staging Classication System Is Endorsed by the American Association of Clinical Endocrinologists, the International Society for Pediatric and Adolescent Diabetes, and The Leona M. and Harry B. Helmsley Charitable Trust Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identi- able stages prior to the onset of symptoms. Stage 1 is dened as the presence of b-cell autoimmunity as evidenced by the presence of two or more islet autoanti- bodies with normoglycemia and is presymptomatic, stage 2 as the presence of b-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classication provides a standardized taxonomy for type 1 diabetes and will aid the development of ther- apies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benet/risk ratio that will impact regulatory approval, reimbursement, and adoption of interven- tions in the early stages of type 1 diabetes to prevent symptomatic disease. Type 1 diabetes is a chronic autoimmune disease with both genetic and environ- mental contributions that results over time in an immune-mediated loss of func- tional pancreatic b-cell mass, leading to symptomatic diabetes and lifelong insulin dependence (13). The disorder represents a disease continuum that begins prior to its symptomatic manifestations. The risk of developing symptomatic type 1 diabetes can be identied and quantied, the disease can be characterized into well- Continue reading >>

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association.

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association.

Home Research Outputs Staging Presymptomatic Type 1 Diabetes: A Scientific Stateme... Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Research output: Contribution to journal Article Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of -cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of -cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease. Benaroya Research Institute at Virginia Mason Continue reading >>

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement Of Jdrf, The Endocrine Society, And The American Diabetes Association

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society IPH presents results of a study of the lifetime cost of childhood obesity on the island of Ireland at the Summer Scientific Meeting 2018 The Faculty of Public Health's Annual Summer Scientific Meeting was held on 30th & 31st of May 2018in Dublin.Professor Kevin P. Balanda from the IPH presented the results from the 'Lifetime financial costs of childhood obesity/overweight in Ireland and Northern Ireland'. The JANPA/safefood project estimated that the obesity/overweight in the island's 2015 childhood population was associated with lifetime excess financial costs of 7.1 (in 2015 values). Direct health care costs accounted for approximately 25% of this total costs. The biggest cost category was lost productivity due to premature death that accounted for approximately 60% of total excess lifetime costs on the island. The study highlights gender differences and North/South differences in the magnitude of the cost categories. IPH contributes to the JANPA Skills Building Workshopto ECO2018 The ECO2018 Congress on Obesity was held from 23rd to 26th of May 2018in Vienna, Austria.Professor Kevin P. Balanda from the IPH contributed a session to the JANPA Workshop. The brief session looked atmobilising data and research to estimate the lifetime costs of childhood obesityusing the JANPA costing model. Itoutlined thedata and research required, describedsome of the challenges and gave tips for overcoming thesechallenges. It ended with a brief overview of the opportunities that exist for countries in conducting such study in their country. Co Continue reading >>

New Insights Into The Progression Of Type 1 Diabetes

New Insights Into The Progression Of Type 1 Diabetes

If you have Type 1 diabetes or know someone who does, you’re likely aware that this type of diabetes is an autoimmune disorder that results in the destruction of the beta cells (the cells that make insulin) in the pancreas. Having Type 1 diabetes means having to take lifelong insulin injections, and people who are diagnosed with this condition must start on insulin right away. Type 1 diabetes progresses Type 2 diabetes, the “other” type of diabetes, is a whole different ball of wax. This type of diabetes partly stems from insulin resistance, meaning that the pancreas produces insulin but the body has a hard time using it. Type 2 diabetes is often described as being “progressive”: caught in the early stages, for example, it’s possible to manage it through healthy eating, weight loss (if necessary), and physical activity. But over time, many people require the help of medication, often in the form of diabetes pills, and then, perhaps, noninsulin injectable meds. Eventually, insulin injections may be needed. In the case of Type 1 diabetes, researchers now believe that this disease also progresses at predictable rates and stages before a person develops signs and symptoms. The discovery of these stages is a big deal, as it will enable researchers to find ways to intervene to delay and hopefully prevent progression to the onset of symptoms and lifelong insulin dependence. Stages of Type 1 diabetes The discovery of the various stages leading up to symptomatic Type 1 diabetes are outlined in the October 2015 issue of the journal Diabetes Care. The paper is entitled “Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.” Here’s a closer look at the crux of this paper. Stage 1: Auto Continue reading >>

More in diabetes